HK1245276B - 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法 - Google Patents

新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法 Download PDF

Info

Publication number
HK1245276B
HK1245276B HK18104469.4A HK18104469A HK1245276B HK 1245276 B HK1245276 B HK 1245276B HK 18104469 A HK18104469 A HK 18104469A HK 1245276 B HK1245276 B HK 1245276B
Authority
HK
Hong Kong
Prior art keywords
calmangafodipir
use according
mangafodipir
manganese
pharmaceutical composition
Prior art date
Application number
HK18104469.4A
Other languages
English (en)
Chinese (zh)
Other versions
HK1245276A1 (en
Inventor
扬．奥洛夫．卡尔松
揚．奧洛夫．卡爾松
卡尔．赖内克
蒂诺．库尔茨
卡爾．賴內克
罗尔夫．安德森
迈克尔．哈尔
蒂諾．庫爾茨
克里斯蒂娜．麦克劳克林
斯文．雅各布松
羅爾夫．安德森
雅克．内斯特伦
邁克爾．哈爾
克里斯蒂娜．麥克勞克林
雅克．內斯特倫
Original Assignee
爱基提斯治疗公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 爱基提斯治疗公司 filed Critical 爱基提斯治疗公司
Publication of HK1245276A1 publication Critical patent/HK1245276A1/xx
Publication of HK1245276B publication Critical patent/HK1245276B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C07F19/005—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00 without metal-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18104469.4A 2012-01-05 2018-04-04 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法 HK1245276B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261583377P 2012-01-05 2012-01-05
US61/583,377 2012-01-05
US201261656178P 2012-06-06 2012-06-06
US61/656,178 2012-06-06
US201261668679P 2012-07-06 2012-07-06
US61/668,679 2012-07-06
US201261721575P 2012-11-02 2012-11-02
US61/721,575 2012-11-02

Publications (2)

Publication Number Publication Date
HK1245276A1 HK1245276A1 (en) 2018-08-24
HK1245276B true HK1245276B (zh) 2020-05-08

Family

ID=47559596

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18104469.4A HK1245276B (zh) 2012-01-05 2018-04-04 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法

Country Status (15)

Country Link
US (3) US9187509B2 (https=)
EP (1) EP2800755B1 (https=)
JP (2) JP6131271B2 (https=)
KR (1) KR102086022B1 (https=)
CN (2) CN107353313B (https=)
AU (1) AU2012364227B2 (https=)
BR (1) BR112014016497B1 (https=)
CA (1) CA2862736C (https=)
ES (1) ES2683038T3 (https=)
HK (1) HK1245276B (https=)
IN (1) IN2014MN01495A (https=)
MX (1) MX2014008247A (https=)
RU (2) RU2622646C2 (https=)
WO (1) WO2013102806A1 (https=)
ZA (1) ZA201404904B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187509B2 (en) 2012-01-05 2015-11-17 Pled Pharma AB Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
KR20150080616A (ko) * 2012-11-02 2015-07-09 플레드파르마 에이비 암 치료 방법
US10233205B2 (en) 2015-08-07 2019-03-19 Auburn University Magnetic resonance imaging contrast agent capable of detecting hydrogen peroxide and reducing reactive oxygen species
EP3402475B1 (en) 2016-01-11 2021-10-20 Egetis Therapeutics AB Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
CN110139673B (zh) * 2016-11-14 2022-03-22 卡尔森图纳投资公司 使用非过渡金属配位的二吡哆基化合物以预防和治疗化疗诱发的psn
CN117279657A (zh) 2021-05-18 2023-12-22 日本株式会社Ltt生物医药 用于治疗或预防伴随抗癌剂给药的障碍的医药组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223243A (en) 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
AR246956A1 (es) * 1987-05-08 1994-10-31 Salutar Inc Compuesto quelante, un intermediario para preparar el mismo, y un procedimiento para preparar una composicion de medio de contraste.
US5091169A (en) 1987-05-08 1992-02-25 Salutar, Inc. Dipyridoxyl phosphate NMRI contrast agent compositions
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
GB9613182D0 (en) * 1996-06-24 1996-08-28 Nycomed Imaging As Method
GB9727224D0 (en) 1997-12-23 1998-02-25 Nycomed Imaging As Method
AU1770299A (en) 1997-12-23 1999-07-19 Nycomed Imaging As Nitric oxide releasing chelating agents and their therapeutic use
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
DE10359628A1 (de) 2003-12-18 2005-07-21 Oxeno Olefinchemie Gmbh Katalysator und Verfahren zur Herstellung von 1-Olefinen aus 2-Hydroxyalkanen
US20070148154A1 (en) 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
BRPI0820832A2 (pt) * 2007-12-14 2015-06-16 Pledpharma Ab Composto, uso de um composto, método de tratamento de câncer, composição farmacêutica, kit , e, uso de uma composição farmacêutica.
US8414866B2 (en) * 2007-12-17 2013-04-09 Ge Healthcare As Method of magnetic resonance imaging of the heart with paramagnetic MN2+
CN102481295A (zh) * 2009-07-06 2012-05-30 普莱制药公司 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法
US9187509B2 (en) * 2012-01-05 2015-11-17 Pled Pharma AB Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment

Also Published As

Publication number Publication date
RU2622646C2 (ru) 2017-06-19
RU2014132184A (ru) 2016-02-27
CA2862736A1 (en) 2013-07-11
JP6316479B2 (ja) 2018-04-25
KR20140117480A (ko) 2014-10-07
US20170165281A1 (en) 2017-06-15
JP6131271B2 (ja) 2017-05-17
RU2017119660A3 (https=) 2020-07-30
US9187509B2 (en) 2015-11-17
ZA201404904B (en) 2024-01-31
HK1203203A1 (en) 2015-10-23
WO2013102806A1 (en) 2013-07-11
KR102086022B1 (ko) 2020-03-06
CN104169291A (zh) 2014-11-26
ES2683038T3 (es) 2018-09-24
RU2765805C2 (ru) 2022-02-03
CA2862736C (en) 2020-09-08
BR112014016497B1 (pt) 2021-02-23
CN107353313B (zh) 2019-04-09
JP2017132801A (ja) 2017-08-03
EP2800755B1 (en) 2018-05-30
EP2800755A1 (en) 2014-11-12
CN104169291B (zh) 2017-08-15
CN107353313A (zh) 2017-11-17
BR112014016497A8 (pt) 2017-07-04
JP2015504066A (ja) 2015-02-05
AU2012364227B2 (en) 2017-12-07
IN2014MN01495A (https=) 2015-04-17
US9597334B2 (en) 2017-03-21
US20160038507A1 (en) 2016-02-11
BR112014016497A2 (pt) 2017-06-13
AU2012364227A1 (en) 2014-07-24
MX2014008247A (es) 2015-03-09
US10111893B2 (en) 2018-10-30
RU2017119660A (ru) 2018-11-08
US20150005259A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
HK1245276B (zh) 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法
HK1245276A1 (en) Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
EP0329737B1 (en) Tri-aza macrocycles and metal complexes thereof
EP1420019B1 (en) Substituted pyridino pentaazamacrocyle ligands
JPH02501141A (ja) テトラ‐アザ大環状化合物およびその金属錯体
JP2003501432A (ja) ペルオキシ亜硝酸塩分解触媒およびその使用方法
Zhao et al. Anti-tumoral titanium (IV) complexes stabilized with phenolato ligands and structure-activity relationship
AU2010269849B2 (en) Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
US6589966B1 (en) Cytotoxic metal chelators and methods for making and using same
EP1904060B1 (en) Use of phthalocyanine derivates for the non-photodynamic treatment of diseases
HK1203203B (en) Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
JP2007075058A (ja) 新規なカタラーゼ金属ポルフィリン錯体複合体、及びそれを含有してなる抗酸化組成物
EP2340020B1 (en) Manganese and cobalt complexes, their preparation and use
CN120647644A (zh) 用于肿瘤化学免疫治疗的铜增生抑制剂及其应用
JP2019535823A (ja) 化学療法で誘発されたｐｓｎを防止および処置するための非遷移金属配位ジピリドキシル化合物の使用